Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12009754 | 0.88 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL12009758 | 0.88 | CNR1 (0.75) | CNR1CNR2 | |
| SCHEMBL30944012 | 0.85 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL30944092 | 0.84 | CNR1 (0.80) | CNR1CNR2 | |
| Otenabant SCHEMBL1622757 | 0.82 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL30944079 | 0.82 | CNR1 (0.77) | CNR1CNR2 | |
| SCHEMBL12009760 | 0.82 | CNR1 (0.53) | CNR1CNR2 | |
| Otenabant SCHEMBL3932007 | 0.81 | CNR1 (0.98) | CNR1CNR2 | |
| SCHEMBL5235768 | 0.77 | CNR1 (0.88) | CNR1CNR2 | |
| SCHEMBL5370899 | 0.77 | CNR1 (0.73) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252791-B2 | Purine compounds as cannabinoid receptor blockers | JENRIN DISCOVERY, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100041650-A1 | PURINE COMPOUNDS AS CANNABINOID RECEPTOR BLOCKERS | JENRIN DISCOVERY (US) | 2010-02-18 | — | — | US | disclosed |
| WO-2010019762-A1 | PURINE COMPOUNDS AS CANNABINOID RECEPTOR BLOCKERS | JENRIN DISCOVERY (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041650-A1 | PURINE COMPOUNDS AS CANNABINOID RECEPTOR BLOCKERS | CNR1, CNR2, P2RY1 | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.